Company Overview and News

7
Why Oppenheimer Sees 30% Upside in Citigroup

2018-09-19 247wallst
Citigroup, Inc. (NYSE: C) just received one of its most bullish analyst calls that is currently available. The money center bank has come back as a dividend payer, and Oppenheimer has raised its target to $95 from $92 while reiterating its current Outperform rating.
C TRI CIT

2
CIT / CIT Group, Inc. (The) null

2018-09-07 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C8Y(# @;V)J#3P\+TQI;F5A8F)D [email protected]&)@8%H%(ADK$"2+/%C<#$0R\X#93[email protected]\DY8#(5K$L=K'(-6,05 M2#+R1(/8!D) \O_R. 8FH%U70") M0- [email protected]/(&(, I0L+/PT*96YD
CIT

2
CIT / CIT Group, Inc. (The) null

2018-09-07 sec.gov
CORRESP John Fawcett Executive Vice President & Chie
CIT

2
CIT / CIT Group, Inc. (The) null

2018-09-07 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0P(# @;V)J#3P\+TQI;F5A
CIT

2
Peapack-Gladstone Bank Hires Kenneth R. Geiger, Senior Vice President, Special Assets

2018-08-28 globenewswire
BEDMINSTER, N.J., Aug. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market: PGC) and Peapack-Gladstone Bank are proud to announce the appointment of Kenneth R. Geiger as Senior Vice President, Special Assets at Peapack-Gladstone Bank. Working out of the Bank’s Headquarters in Bedminster, New Jersey, Mr. Geiger’s primary role includes managing various workout situations and processes for the Bank.
CIT

31
Bruce Berkowitz, From 'The Best Manager Of The 2000s' To Underperforming In Recent Years: The Bets Of An Unconventional Fund Manager

2018-08-28 seekingalpha - 2
Bruce Berkowitz manages Fairholme Fund (FAIRX), a non-diversified mutual fund focused on the US market that has beat the S&P 500 since its inception in 1999.
FNMA SHLD FMCKI FMCKJ MS GGP IPMLF CIT III FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL BRK.A FMCC FAIRX SHLDW FMCCS FMCCT

8
Top Analyst Upgrades and Downgrades: AK Steel, Bloom Energy, Chipotle, CIT, Cushman & Wakefield, Foot Locker, Sonos, US Steel and More

2018-08-27 247wallst - 1
Stocks were indicated to open higher on Monday. Despite the S&P 500 hitting all-time highs a week ago, trading has been very mixed during a very strong earnings season. Investors have seen less reward in 2018 after buying every market dip than had been seen in the past few years. Now investors are deciding how they want their investments positioned ahead of the midterm elections and during international trade concerns.
CWK CMG BE AEO TRI AKS FL MS CIT

2
Why Is CIT Group (CIT) Up 4.3% Since Last Earnings Report?

2018-08-23 zacks
It has been about a month since the last earnings report for CIT Group (CIT - Free Report) . Shares have added about 4.3% in that time frame, outperforming the S&P 500.
CIT

2
DealBook Briefing: Trump’s Wounded. Will Business Feel the Pain? - The New York Times

2018-08-22 nytimes
President Trump’s White House has been dealt its most serious blows yet. The guilty plea by Michael Cohen, his former personal lawyer, and the conviction of Paul Manafort, his former campaign manager, will rock the administration. Especially damaging: Mr. Cohen’s admission to paying a porn star hush money at Mr. Trump’s request, apparently violating campaign finance laws.
NYTAB CIT

9
U.S. business borrowing for equipment rises 4 pct in July - ELFA

2018-08-22 reuters
(Reuters) - U.S. companies’ borrowing to spend on capital investments rose 4 percent in July from a year earlier, a trade group representing capital equipment lenders said on Wednesday.
CATR CAT VOLVF CAJ VZ VOLVY VOLAF CIT VLVLY VZA

2
Uber hires CFO on the road to IPO

2018-08-22 livemint
San Francisco: Uber has named a news chief financial officer as the smartphone-summoned ride service remained on the road to a stock market debut next year. Nelson Chai came on board from Chicago-based insurance firm Warranty Group, where he was chief executive, according to Uber.
CIT

2
Uber appoints new head of finance as it readies for IPO

2018-08-21 sfgate
After a yearslong search, Uber has finally found a chief financial officer as it advances toward an initial public offering.
DTK CIT

2
Uber hires CFO after lengthy search, paving way for IPO

2018-08-21 channelnewsasia
Uber Technologies Inc has hired a chief financial officer, the ride-services company said on Tuesday, filling a long-standing vacancy and clearing the way for a much-anticipated initial public offering next year.
DTK CIT

2
Uber hires CFO after lengthy search, paving way for IPO

2018-08-21 reuters
SAN FRANCISCO (Reuters) - Uber Technologies Inc [UBER.UL] has hired a chief financial officer, the ride-services company said on Tuesday, filling a long-standing vacancy and clearing the way for a much-anticipated initial public offering next year.
DTK CIT

2
CIT / CIT Group, Inc. (The) FORM 8-K (Current Report)

2018-08-17 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CIT

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 125581801